Company intelligence / Profile preview
BreStem Therapeutics
Raleigh, North Carolina, United Statesbrestem.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BreStem’s lead candidate, BRS101, is the world’s first IND using intrinsic lung-derived cells to treat pulmonary conditions. It is currently in Phase 1 clinical trials for idiopathic pulmonary fibrosis. The company also has multiple preclinical candidates targeting other lung diseases using cell therapy and exosome-based approaches. Their approach aims to regenerate damaged lung tissue rather than just slow disease progression. No published clinical results as of June 2025.
- Therapeutic areas
- Pulmonology
- Modalities
- Cell therapyExosome-based therapySmall molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on BreStem Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BreStem Therapeutics.